Browse the evidence

Tirzepatide significantly reduces HbA1c and body weight in adults with Type 1 Diabetes (T1D) without increasing the risk of diabetic ketoacidosis (DKA) or time below range.

If you have Type 1 Diabetes and struggle with weight or high blood sugar despite insulin, ask your doctor about tirzepatide. This study shows it can lower your A1c and help you lose significant weight (over 10% in some cases) without increasing the risk of dangerous ketones or low blood sugar, provided it is managed carefully by a specialist.

Newer emerging anti-obesity medications, specifically GLP-1/GIP/Glucagon receptor agonists (e.g., tirzepatide, retatrutide), demonstrate superior weight loss efficacy compared to older single-mechanism drugs.

Newer drugs like tirzepatide (Mounjaro/Mounjaro) can lead to nearly 21% weight loss in some patients, significantly higher than older drugs. These require weekly injections and are more expensive. Discuss with your doctor if the higher efficacy justifies the cost and injection burden for your specific health goals.

Bariatric surgery can yield significant long-term improvements in cardiometabolic risk factors (fasting glucose, blood pressure, triglycerides, medication reduction) even in patients who fail to achieve substantial weight loss (defined as <25% excess weight loss).

If you undergo bariatric surgery and do not lose a large amount of weight, do not assume the procedure has failed. Significant improvements in blood sugar, blood pressure, and medication needs are still possible due to the physiological changes the surgery induces, not just the weight loss. Monitor your metabolic markers closely regardless of the scale.

Sarcopenic obesity in elderly women is associated with significantly lower muscle strength and lean body mass, along with elevated pro-inflammatory markers (specifically IL-6) and glucose levels compared to nonsarcopenic obesity.

For elderly women, carrying excess fat combined with low muscle mass is worse for inflammation and strength than carrying excess fat alone. Screening for 'sarcopenic obesity' using appendicular lean mass relative to BMI can identify those at highest risk for disability, allowing for earlier, targeted strength and nutrition interventions.

Modern obesity pharmacotherapies (phentermine/topiramate, lorcaserin, bupropion/naltrexone) improve cardiovascular risk factors (blood pressure, lipids, glucose) but their impact on actual cardiovascular events and mortality remains unproven and requires dedicated outcomes trials.

While these medications effectively lower weight and improve markers like blood pressure and blood sugar, they are not yet proven to prevent heart attacks or strokes. They should be viewed as tools for risk factor management rather than guaranteed cardiovascular protection, and their use requires careful monitoring for side effects.

Acute moderate-intensity aerobic exercise significantly reduces circulating levels of acylated ghrelin and leptin in overweight women, while having no effect on obestatin or des-acyl ghrelin.

If you are an overweight woman, doing 60 minutes of moderate running (about half your max capacity) will likely lower your hunger hormones (ghrelin) and satiety signals (leptin) for about an hour after you finish. It does not affect obestatin. This suggests moderate cardio might not spike hunger as feared in this demographic, though individual responses vary.

A ketogenic diet (KD) improves insulin sensitivity and reduces insulin requirements in patients with type 2 diabetes and obesity by lowering glycemic response and reducing pancreatic insulin secretion.

To improve insulin sensitivity, restrict carbohydrates to under 50g per day while maintaining high fat intake (approx 75% of calories) and moderate protein (1-1.4g/kg). Expect initial side effects like fatigue or 'keto flu' due to electrolyte shifts, which typically resolve as your body adapts.

GLP-1 receptor agonists (semaglutide, tirzepatide) and bariatric surgery (RYGB) extend the duration of weight loss prior to plateau by weakening the physiological appetite feedback control circuit, whereas diet restriction fails to weaken this circuit and thus plateaus within ~12 months.

If you are using GLP-1s or had surgery, your prolonged weight loss is due to a physiological change in how your body regulates appetite, not just willpower. Dieting alone triggers a strong appetite feedback loop that causes early plateaus; these interventions bypass that loop.

Dual (GLP-1/GIP) and Triple (GLP-1/GIP/Glucagon) receptor agonists offer superior weight loss and metabolic benefits compared to GLP-1 mono-agonism by leveraging complementary mechanisms.

Newer multi-agonists (dual/triple) like retatrutide show much higher weight loss (up to 24%) than older GLP-1 drugs. They work by hitting multiple metabolic targets at once, which may be necessary for patients who don't respond sufficiently to GLP-1 alone.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors (GCGR) offer additional metabolic benefits, including increased energy expenditure and weight loss, by combining the insulinotropic effects of incretins with the lipolytic and anorectic effects of glucagon.

For patients with Type 2 Diabetes and obesity who need more than standard treatment, triple-agonist medications (targeting GLP-1, GIP, and Glucagon) are in early development. These drugs aim to boost weight loss and energy expenditure by leveraging the body's natural hormonal responses to food. Because they are still in early trials, their long-term safety and optimal dosing are not yet fully established, but they represent a promising next step for complex metabolic cases.

Tirzepatide demonstrates potential for cardiovascular protection, including reduced risk of major adverse cardiovascular events (MACE-4) and improved lipid profiles, in patients with Type 2 Diabetes.

Beyond lowering blood sugar, Tirzepatide may improve heart health by lowering bad cholesterol and triglycerides and reducing the risk of heart attacks and strokes. This is particularly important for diabetic patients with existing heart risks.

Tirzepatide shows promise for treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by reducing liver fat content and improving liver enzymes, likely through indirect weight loss and metabolic effects.

For diabetics with fatty liver, Tirzepatide may help reduce liver fat and improve liver enzymes, likely by aiding weight loss and metabolic health. However, more specific clinical trials are needed to confirm its efficacy as a primary treatment for NASH.

Short-term testosterone replacement therapy (200mg intramuscular testosterone cypionate every 3 weeks for 6 months) significantly improves libido and reduces waist circumference in males with late-onset hypogonadism.

If you are a man over 50 with clinically diagnosed low testosterone, short-term testosterone replacement therapy (200mg every 3 weeks) can significantly improve your sex drive and reduce belly fat within 6 months. This study also found no dangerous spikes in prostate markers or blood thickness during this period, suggesting it can be safe with proper monitoring.

Diets high in rapidly digestible carbohydrates increase the insulin-to-glucagon ratio, shifting energy partitioning toward adipose storage and away from metabolically active tissues, which triggers compensatory hunger and reduced metabolic rate.

To manage weight, focus on reducing rapidly digestible carbohydrates (refined grains, added sugars) to lower insulin levels. This prevents the hormonal trapping of energy in fat cells and reduces the biological drive to overeat and slow metabolism.

Lifestyle interventions (diet and exercise) combined with GLP-1 receptor agonists (GLP-1RAs) may mitigate gastrointestinal side effects and enhance weight loss, though their efficacy requires confirmation via randomized controlled trials.

If you are taking a GLP-1RA, do not abandon lifestyle changes. Focus on dietary strategies like smaller, lower-fat meals to manage nausea and other side effects. This may help you stay on the medication longer and potentially achieve greater weight loss, although more research is needed to confirm these benefits.

In obese patients with preexisting hip or knee osteoarthritis, GLP-1 receptor agonist use is associated with a significantly reduced odds of conversion to total joint arthroplasty (THA and TKA) within one year, independent of weight loss.

If you are obese and have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist (like semaglutide or liraglutide) is associated with a lower risk of needing joint replacement surgery within a year, even if your weight doesn't change significantly. This suggests the drug may have direct protective effects on your joints, not just benefits from weight loss. Discuss this potential benefit with your doctor, especially if you are considering these medications for weight management or diabetes.

GLP-1 receptor agonists (GLP-1RAs) promote significant weight loss and BMI reduction in people with HIV (PWH), with tirzepatide and longer treatment duration (>6 months) being the strongest predictors of achieving >5% weight loss.

If you have HIV and are struggling with weight gain, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a proven, effective treatment option. The study shows that sticking with the medication for more than 6 months and reaching the maximum dose significantly increases your chances of losing more than 5% of your body weight. Tirzepatide, in particular, showed the strongest association with significant weight loss in this population.

Supplementing meals with 3-4 grams of leucine can improve or normalize muscle protein synthesis in aging muscle, acting as a trigger for the mTOR pathway.

If you are older, adding 3-4 grams of leucine to your meals (or eating leucine-rich foods like beef or whey) can help trigger muscle growth. However, if you already eat enough protein, you might not need extra leucine supplements.

Eloralintide (LY3841136), a selective amylin receptor agonist, promotes significant body weight loss primarily through fat mass reduction with favorable gastrointestinal tolerability compared to non-selective amylin agonists.

Eloralintide is a once-weekly injection that targets specific receptors to reduce appetite and food intake. In early trials, it led to modest but significant weight loss (up to 4.4% in 4 weeks) primarily by burning fat, with fewer stomach side effects than some competitors. It is currently in early clinical stages and not yet widely available.

In people with type 2 diabetes, objectively assessed moderate-to-vigorous physical activity (MVPA) is inversely associated with systemic inflammatory markers IL-6, IL-1ra, and MCP-1, with the association being largely mediated by adiposity (BMI).

For people with Type 2 Diabetes, engaging in moderate-to-vigorous physical activity (like brisk walking) for just 10-minute increments daily is associated with lower levels of key inflammatory markers (IL-6, IL-1ra). While weight loss (BMI) plays a significant role in this benefit, the act of moving itself also reduces inflammation through non-weight-related mechanisms. Focus on consistent, moderate-intensity movement rather than just weight loss metrics.

Daily administration of 100 mg mirabegron (a selective β3-AR agonist) increases energy expenditure and skin temperature in humans without cardiovascular side effects, offering a pharmacological alternative to cold exposure for activating brown adipose tissue.

If you are looking to boost metabolic rate through medication, 100 mg of mirabegron daily has been shown in studies to increase energy expenditure and skin temperature without causing heart issues. This is a repurposed drug originally for bladder issues, but it targets fat-burning pathways. Note that higher doses (150-200mg) may cause heart rate and blood pressure increases, so 100mg is the identified safe effective dose in the cited research.

GLP-1 receptor agonists (GLP-1RAs) are perceived by current and past users as safe and effective for weight loss, with users strongly disagreeing that risks outweigh benefits, whereas non-users exhibit significant skepticism regarding safety and efficacy.

If you are considering GLP-1RAs, be aware that skepticism about safety and cost are common barriers, especially if you haven't used them. However, data from current and past users shows they strongly disagree that risks outweigh benefits and highly recommend the medication. Consult a healthcare provider to address specific safety concerns and cost barriers, as user experience often contradicts public skepticism.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) significantly reduce rheumatoid arthritis (RA) disease activity and pain in patients with RA and overweight or obesity, independent of the magnitude of weight loss.

If you have Rheumatoid Arthritis and are overweight, GLP-1 medications (like Ozempic or Mounjaro) may help reduce your joint pain and disease activity, not just help you lose weight. This benefit appears to come from the drug's direct effect on inflammation, not just the weight loss itself. Be aware that stomach side effects are common and insurance coverage can be a hurdle, but the potential for improved RA control is a significant clinical benefit to discuss with your rheumatologist.

Lorcaserin IR (twice daily) improves smoking cessation rates and prevents post-cessation weight gain in overweight or obese smokers compared to placebo.

If you smoke and are overweight, lorcaserin (10 mg twice daily) can help you quit smoking and prevent the weight gain that often follows. It works by reducing cravings and managing weight. This use is not FDA-approved, so discuss risks and benefits with your doctor.